BioMarin Pharmaceutical agreed to acquire Alesta Therapeutics for $275 million upfront, aiming to expand in the rare bone disease market and intensify competition with AstraZeneca in that segment. The acquisition structure reflects BioMarin’s intent to strengthen its pipeline with a focused commercial and development-ready asset. The deal also highlights the ongoing premium placed on late-stage or near-commercial rare-disease programs, where label expansion and market-access momentum can drive outsized returns. BioMarin positioned the move as a strategic step to broaden its bone portfolio. Regulatory and closing timelines were not detailed in the excerpt, but investors will likely watch how quickly BioMarin integrates development plans and evaluates pipeline synergies across modalities.